by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Preclinical respiratory efficacy studies are an important part of developing new treatments for diseases affecting the lungs and airways. Before a candidate progresses towards clinical development, researchers need evidence that it produces a relevant biological or...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Airway hyperresponsiveness is a key feature of asthma and an important endpoint in preclinical respiratory drug development. It describes an exaggerated narrowing of the airways in response to stimuli that produce a smaller response in healthy airways. Measuring this...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Developing a new respiratory therapeutic requires a clear understanding of disease biology, drug activity and the evidence needed to progress a candidate through preclinical development. For pharmaceutical and biotechnology companies, accessing the right preclinical...
by Virtus | Oct 18, 2026 | Respiratory Preclinical Research
Choosing the right respiratory CRO (Contract Research Organisation) can be an important decision for pharmaceutical and biotechnology companies developing new treatments for respiratory disease. Preclinical respiratory research involves more than selecting an...
by Virtus | Oct 11, 2026 | Scientific Advisory Board
Professor David Jackson David Jackson, FRCP, MSc, PhD, is Professor of Respiratory Medicine at King’s College London and Clinical Director for Guy’s Severe Asthma Centre at Guy’s and St Thomas’ NHS Foundation Trust in London. Since 2024, he has also assumed clinical...